Findings to be Presented at Annual Scientific Session of the American College of Cardiology (ACC) About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO(R) March 15, 2015, 4:15PM PT: Post-Marketing Pharmacovigilance Study for the Active Detection and Evaluation of Major Bleeding in Rivaroxaban Users with Non-Valvular Atrial Fibrillation

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors RARITAN, N.J., March 2, 2015 /PRNewswire/ -- Additional findings to be pres...

Full description

Saved in:
Bibliographic Details
Published inPR Newswire
Format Newsletter
LanguageEnglish
Published New York PR Newswire Association LLC 02.03.2015
Subjects
Anticoagulants
Blood clots
Cardiac arrhythmia
Cardiology
Clinical medicine
Clinical trials
Collaboration
Drug dosages
Epidural
Lungs
Medical treatment
Medicine
Observational studies
Regulatory approval
Stroke
Surgery
Thrombosis
RARITAN, N.J
Online AccessGet full text

Cover

More Information
Summary:A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors RARITAN, N.J., March 2, 2015 /PRNewswire/ -- Additional findings to be presented at the meeting include new 24-month results from an ongoing, five-year, observational study of people with non-valvular atrial fibrillation taking XARELTO(R), which showed the rates and patterns of major bleeding in routine clinical practice were generally consistent with those observed in Phase 3 clinical trials used to approve the medicine for this indication.